Literature DB >> 13233522

The effect of gamma globulin on sub clinical infection in familial associates of poliomyelitis cases. II. Serological studies and virus isolations from pharyngeal secretions.

G C BROWN, A S RABSON, J H SCHIEBLE.   

Abstract

Entities:  

Keywords:  GAMMA GLOBULIN; PHARYNX/bacteriology; POLIOMYELITIS VIRUS/culture

Mesh：

Substances：

Year:  1955        PMID： 13233522

Source DB:  PubMed          Journal:  J Immunol        ISSN： 0022-1767            Impact factor:   5.422


× No keyword cloud information.
  7 in total

1.  [Laboratory diagnosis of neural virus infections; technic and results of pathogen detection].

Authors:  H LENNARTZ; W KLONE; B ROHDE
Journal:  Klin Wochenschr       Date:  1957-09-15

2.  The incidence of infection among contacts of poliomyelitis cases.

Authors:  D M HORSTMANN; R W MCCOLLUM; A D MASCOLA
Journal:  J Clin Invest       Date:  1955-10       Impact factor: 14.808

3.  Serologic Response of Infants to a Multiple Vaccine for Simultaneous Immunization Against Diphtheria, Pertussis, Tetanus, and Polio-myelitis, in Relation to the Presence of Specific Maternal Antibody.

Authors:  G C Brown; P L Kendrick
Journal:  Am J Public Health Nations Health       Date:  1960-10

4.  Poliomyelitis: problems in pathogenesis and immunization.

Authors:  D M HORSTMANN
Journal:  Yale J Biol Med       Date:  1957-11

5.  Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months.

Authors:  Xavier Sáez-Llorens; Birgit Thierry-Carstensen; Lina Saem Stoey; Charlotte Sørensen; Henrik Wachmann; Ananda S Bandyopadhyay; Pernille Ingemann Nielsen; Mie Vestergaard Kusk
Journal:  Vaccine       Date:  2020-04-06       Impact factor: 3.641

6.  Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.

Authors:  Lulu C Bravo; Josefina C Carlos; Salvacion R Gatchalian; May Emmeline B Montellano; Charissa Fay Corazon B Tabora; Birgit Thierry-Carstensen; Pernille Nyholm Tingskov; Charlotte Sørensen; Henrik Wachmann; Ananda S Bandyopadhyay; Pernille Ingemann Nielsen; Mie Vestergaard Kusk
Journal:  Vaccine       Date:  2019-11-05       Impact factor: 3.641

7.  Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.

Authors:  Xavier Sáez-Llorens; Milagros Chan; Rodrigo DeAntonio; Torben Petersen; Charlotte Olesen; Jens Søndergaard Jensen; Charlotte Sørensen; Lena Messerschmidt Ekstrand; Michaela Katrine Czort; Hans-Henrik Kristensen; Niels Thulstrup; Dorte Birk Christoffersen
Journal:  Vaccine       Date:  2022-09-03       Impact factor: 4.169
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.